Professor Alfred Cheung
Salt Lake City (United States of America)
Empagliflozin decreases risk of kidney function decline in type 2 diabetes: slope analyses in patients with and without heart failure at baseline from the EMPA-REG OUTCOME trial.
Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure
Topic: Miscellaneous
Session: Late Breaking Trials II: Focus on chronic heart failure
ESC 365 is supported by
